Pfizer Reports Results of Bavencio (avelumab) + Inlyta (axitinib) in P-III JAVELIN Renal 101 trial for 1L Advanced Renal Cell Carcinoma (RCC)

 Pfizer Reports Results of Bavencio (avelumab) + Inlyta (axitinib) in P-III JAVELIN Renal 101 trial for 1L Advanced Renal Cell Carcinoma (RCC)

Pfizer Reports Results of Bavencio (avelumab) + Inlyta (axitinib) in P-III JAVELIN Renal 101 trial for 1L Advanced Renal Cell Carcinoma (RCC)

Shots:

  • The P-III JAVELIN Renal 101 trial involves assessing of Bavencio (avelumab) + Inlyta (axitinib) vs Sutent (sunitinib) in 886 patients with previously untreated advanced RCC
  • P-III JAVELIN Renal 101 trial results: mPFS (13.8 mos. vs 7.2 mos.); ORR (51.4% vs 25.7%); 39% reduction in risk of disease progression; received anticancer drug therapies (20.8% vs 39.2%); AEs (71.2% vs 71.5%); discontinuations of treatment (7.6% vs 13.4%)
  • Bavencio (avelumab) is an anti-programmed death ligand-1 (PD-L1) Ab, that blocks the interaction between PD-L1 with PD-1 receptors. In Nov 2014 Merck KGaA & Pfizer collaborated to co-develop and co-commercialize Bavencio

Click here to read full press release/ article| Ref: Pfizer | Image: Pfizercentreone

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post